Continuing medical education, professional meetings and scientific conferences are adequate mechanisms by which drug manufacturers can share data about unapproved uses, consumer advocates and academic researchers said Nov. 10 in arguing against any relaxation of FDA restrictions on off-label communications.
During the second day of a two-day FDA hearing, agency officials listened to more than two dozen individuals, the majority of whom suggested that allowing more communications about off-label use...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?